Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 35a Olaparib Maintenance in BRCA Wild-type Advanced Ovarian Cancer
2021-000244-21Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-free survival (PFS). Started Aug 2021; status: active.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2021-000244-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000244-21.